Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diagnostic Prostate Biopsy Clear all
Not listed No phase listed Observational

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

NCT03630926
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hypertrophy, Bladder Stones, Kidney Stones
Interventions
NV-VPAC1 PCa Urine Diagnostic Test
Diagnostic Test
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 10, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Active, not recruiting Phase 2 Interventional

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

NCT05960578
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Completed No phase listed Observational

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

NCT01954004
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 10, 2026, 9:15 AM EDT
Active, not recruiting Early Phase 1 Interventional

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Terminated Not applicable Interventional Results available

Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer

NCT00773773
View directory record Official record
Conditions
Prostate Cancer, Elevated Prostate Specific Antigen (PSA)
Interventions
serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 10, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

NCT02809690
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
CAT, 18F-FMAU, Laboratory Biomarker Analysis, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound
Device · Drug · Other + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 10, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

NCT03933670
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

NCT07185165
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography, Ultrasound-Guided Prostate Biopsy
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Completed No phase listed Observational

Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients

NCT02209584
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 10, 2026, 9:15 AM EDT
Active, not recruiting Phase 1 Interventional

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

NCT00082147
View directory record Official record
Conditions
Prostate Cancer
Interventions
Biopsy
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 10, 2026, 9:15 AM EDT
Suspended Phase 2 Interventional

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

NCT04346225
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Carcinoma
Interventions
Hyperpolarized C13, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Terminated No phase listed Observational

MRI Before Biopsy in Diagnosing Patients With Prostate Cancer

NCT02131207
View directory record Official record
Conditions
Prostate Cancer
Interventions
magnetic resonance imaging, prostate biopsy
Device · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 10, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Optical Tomography in Prostate Cancer

NCT03215992
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diffuse Optical Tomography (DOT) System
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 10, 2026, 9:15 AM EDT
Completed No phase listed Observational

Molecular Mechanisms Underlying Prostate Cancer Disparities

NCT02229565
View directory record Official record
Conditions
Prostate Cancer
Interventions
Biopsy or prostatectomy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 10, 2026, 9:15 AM EDT
Not listed Not applicable Interventional

Prostate Imaging Using MRI +/- Contrast Enhancement

NCT04571840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy
Diagnostic Test
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 10, 2026, 9:15 AM EDT
Completed Phase 1 Interventional

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

NCT00562380
View directory record Official record
Conditions
Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ganitumab, laboratory biomarker analysis, pharmacological study, biopsy
Biological · Other · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 10, 2026, 9:15 AM EDT
Terminated Not applicable Interventional

Guided Biopsy for Mapping Prostate Cancer

NCT01007214
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostatectomy
Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 10, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.

NCT01964638
View directory record Official record
Conditions
Prostate Cancer
Interventions
Targeted Biopsy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 10, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

NCT02141490
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Kidney Cancer
Interventions
Ferumoxytol, Magnetic Resonance Imaging (MRI)
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 9:15 AM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 9:15 AM EDT
Completed No phase listed Observational

Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis

NCT02397629
View directory record Official record
Conditions
Prostate Cancer
Interventions
This study has no intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 10, 2026, 9:15 AM EDT